$THERF recent news/filings

bullish

## source: finance.yahoo.com

Fri, 15 May 2015 15:50:20 GMT ~ Authorization to Discontinue Class Action Proceedings Against Theratechnologies Granted

[at noodls] - AUTHORIZATION TO DISCONTINUE CLASS ACTION PROCEEDINGS AGAINST THERATECHNOLOGIES GRANTED Montreal, Canada - May 15, 2015 - Theratechnologies Inc. (TSX: TH) today announced that the Superior Court of Québec ...

read full: http://www.noodls.com/view/BB1C09E6AF575E5AEC3E3FB4017E9D7BE9E76817
*********************************************************

Fri, 17 Apr 2015 15:08:33 GMT ~ Supreme Court of Canada rules in favour of Theratechnologies

[at noodls] - Montreal, Canada - April 17, 2015 - Theratechnologies Inc. (TSX: TH) announced today that the Supreme Court of Canada has granted its appeal and dismissed 121851 Canada Inc.'s motion for leave to commence ...

read full: http://www.noodls.com/view/886714243D691AE32E1A04C5475D9C75846BAA7F
*********************************************************

Tue, 14 Apr 2015 12:25:55 GMT ~ Theratechnologies Announces Financial Results for First Quarter of 2015

[at noodls] - Montreal, Canada - April 14, 2015 - Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced its financial results for the first quarter ended February 28, 2015. ... This is an abstract of ...

read full: http://www.noodls.com/view/BFE6BB99ACD018FE3570D6C91E7CC3B699F11C16
*********************************************************

Mon, 30 Mar 2015 20:44:36 GMT ~ Health Canada Approves 1mg/vial Presentation of EGRIFTA(TM) (tesamorelin for injection)

[at noodls] - HEALTH CANADA APPROVES 1MG/VIAL PRESENTATION OF EGRIFTA™ (tesamorelin for injection) Montreal, Canada - March 30, 2015 - Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that ...

read full: http://www.noodls.com/view/9BB64F46F15E316D9EAE77B24552097B5F6B2137
*********************************************************

Fri, 27 Feb 2015 16:20:18 GMT ~ Theratechnologies Annouces Commercialization Agreement for Egriftam (Tesamorelin for injection) in Europe

[at noodls] - THERATECHNOLOGIES ANNOUNCES COMMERCIALIZATION AGREEMENT FOR EGRIFTATM (TESAMORELIN FOR INJECTION) IN EUROPE Montreal, Canada - February 27, 2015 - Theratechnologies Inc. (TSX: TH) is pleased to announce ...

read full: http://www.noodls.com/view/76BEDB775425552599C886662ABF983AE7E5E466
*********************************************************

$THERF charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$THERF company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/THERF/company-info
Ticker: $THERF
OTC Market Place: OTC Pink Limited
CIK code: 0001512717
Company name: Theratechnologies Inc.
Company website: http://www.theratech.com
Incorporated In: Canada

Business Description:

$THERF share structure

## source: otcmarkets.com

Market Value: $70,320,821 a/o May 15, 2015
Shares Outstanding: 61,010,603 a/o Nov 30, 2012
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value

$THERF extra dd links

Company name: Theratechnologies Inc.
Company website: http://www.theratech.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/THERF/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/THERF/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=THERF+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=THERF+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=THERF+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/THERF/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/THERF/news - http://finance.yahoo.com/q/h?s=THERF+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/THERF/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/THERF/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/THERF/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/THERF/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/THERF/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/THERF/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/THERF/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/THERF/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=THERF+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/THERF
DTCC (dtcc.com): http://search2.dtcc.com/?q=Theratechnologies+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Theratechnologies+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Theratechnologies+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.theratech.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.theratech.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.theratech.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/THERF/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/THERF
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/THERF/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/THERF/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/THERF/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001512717&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/THERF/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/THERF/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/THERF/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/THERF/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=THERF&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=THERF
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/THERF/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=THERF+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=THERF+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=THERF
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=THERF
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=THERF+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/THERF/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=THERF+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/THERF.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=THERF
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/THERF/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/THERF/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/THERF/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/THERF/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/THERF
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/THERF
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/THERF:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=THERF
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=THERF



$THERF DD Notes ~ http://www.ddnotesmaker.com/THERF

News: http://www.otcmarkets.com/stock/THERF/news

SYMBOL CHANGE TO THERF

$THERF

Theratechnologies Announces Completion of NASDAQ Delisting

http://theratech.com/sites/default/files/news_release_en/delisting_v_3.pdf

on watch

12:51AM Theratechnologies: FDA approves alternative storage conditions for EGRIFTA (THER) 0.39 : Co announces the FDA has granted approval of a Supplemental New Drug Application (sNDA), filed by its commercial partner, EMD Serono, providing for the revision of the EGRIFTA prescribing information, to include storage conditions for the 2 mg vial up to 12 weeks at or below 25 degrees C after dispensing to the patient. Previously, EGRIFTA(TM) could only be stored between 2 degrees C and 8 degrees C (36 degrees F and 46 degrees F) until the expiration date.

Theratechnologies once again tries to slash its way to breakeven point $0.37
By John Carroll Comment | Forward | Twitter | Facebook | LinkedIn

Ten months ago, Montreal-based Theratechnologies ($THER) cut its staff, shelved a mid-stage development program and slashed costs, vowing to get on track to profitability in 2013. And that was the second round of layoffs it engineered in 2011. Today, the biotech went back to the drawing board with yet another round of layoffs and more research cuts as the biotech company lowered its sights to a breakeven position.
In this latest downsizing, Theratechnologies plans to eliminate some 15 R&D positions, suspending most of its in-house research while eliminating the management bonus plan and foregoing any raises for another year. The biotech--which lost CEO John-Michel T. Huss about two weeks ago--says it will complete preclinical work on a next-gen growth hormone releasing peptide.
"Our plan is to become cash neutral rapidly by focusing almost all of our efforts and resources on maximizing revenues from tesamorelin in the near term, while continuing to keep a cap on expenses. By strengthening our base now, we can better assure our success in the future and assess opportunities," said new CEO Luc Tanguay.
Theratechnologies' stock was trading at 37 cents at the market close on Friday.
Tesamorelin was approved by the FDA back in 2010 to treat the buildup of abdominal fat in HIV patients. But sales of the drug, dubbed Egrifta, haven't resolved the company's financial woes. For the first nine months of this year Theratechnologies reported $3.8 million in sales, which was actually down from the same period a year ago as EMD Serono handled the drug launch. R&D costs hit about $4.5 million, half of what it was the prior year.
- here's the press release
Special Report: Top 10 Pharm Theratechnologies once again tries to slash its way to breakeven point
By John Carroll Comment | Forward | Twitter | Facebook | LinkedIn

Ten months ago, Montreal-based Theratechnologies ($THER) cut its staff, shelved a mid-stage development program and slashed costs, vowing to get on track to profitability in 2013. And that was the second round of layoffs it engineered in 2011. Today, the biotech went back to the drawing board with yet another round of layoffs and more research cuts as the biotech company lowered its sights to a breakeven position.
In this latest downsizing, Theratechnologies plans to eliminate some 15 R&D positions, suspending most of its in-house research while eliminating the management bonus plan and foregoing any raises for another year. The biotech--which lost CEO John-Michel T. Huss about two weeks ago--says it will complete preclinical work on a next-gen growth hormone releasing peptide.
"Our plan is to become cash neutral rapidly by focusing almost all of our efforts and resources on maximizing revenues from tesamorelin in the near term, while continuing to keep a cap on expenses. By strengthening our base now, we can better assure our success in the future and assess opportunities," said new CEO Luc Tanguay.
Theratechnologies' stock was trading at 37 cents at the market close on Friday.
Tesamorelin was approved by the FDA back in 2010 to treat the buildup of abdominal fat in HIV patients. But sales of the drug, dubbed Egrifta, haven't resolved the company's financial woes. For the first nine months of this year Theratechnologies reported $3.8 million in sales, which was actually down from the same period a year ago as EMD Serono handled the drug launch. R&D costs hit about $4.5 million, half of what it was the prior year.
- here's the press release
Special Report: Top 10 Pharm

Slapped down hard today.

THTCF namechanged to THER & Uplisted to NASDAQ:

http://www.otcbb.com/asp/dailylist_detail.asp?d=03/08/2011&mkt_ctg=ALL

Theratechnologies (TSX: TH) announced today that the U.S. Food and Drug Administration ("FDA") has approved EGRIFTATM (tesamorelin for injection) as the first and only treatment indicated to reduce excess abdominal fat in HIV-infected patients with lipodystrophy (abdominal lipohypertrophy). EGRIFTATM(tesamorelin for injection) was developed by Theratechnologies and will be exclusively commercialized in the U.S. by EMD Serono, Inc. ("EMD Serono"), an affiliate of Merck KGaA, of Darmstadt, Germany, under the terms of a collaboration and licensing agreement.

There are limitations of use associated with EGRIFTATM (tesamorelin for injection). Since the long-term cardiovascular safety and potential long-term cardiovascular benefit of EGRIFTATM (tesamorelin for injection) treatment have not been studied and are not known, careful consideration should be given whether to continue EGRIFTATM (tesamorelin for injection) treatment in patients who do not show a clear efficacy response as judged by the degree of reduction in visceral adipose tissue ("VAT") measured by waist circumference ("WC") or CT scan. EGRIFTATM (tesamorelin for injection) is not indicated for weight loss management (weight neutral effect). There are no data to support improved compliance with antiretroviral therapies in HIV-positive patients taking EGRIFTATM (tesamorelin for injection).

"Theratechnologies is very pleased to receive marketing approval for EGRIFTATM from the FDA. We are one of the very few Canadian biotechnology companies to have successfully discovered, developed and brought a drug to the market on our own. This milestone represents a significant achievement which will benefit both patients and our shareholders," commented Yves Rosconi, President and CEO of Theratechnologies.

"We are confident that EMD Serono will successfully commercialize EGRIFTATM in the United States, given their track record and expertise with other metabolic disorders," noted Paul Pommier, Chairman of the Board of Directors of Theratechnologies. "Theratechnologies will continue to focus on signing partnerships outside of the United States in order to access additional markets for EGRIFTATM in HIV-infected patients with excess abdominal fat associated with lipodystrophy," Mr. Pommier concluded.

"While antiretroviral therapy is extremely important in the management of patients with HIV infection, some patients are experiencing excess abdominal fat associated with lipodystrophy, which can be difficult to manage," said Fereydoun Firouz, President and CEO, EMD Serono. "EMD Serono has maintained a commitment to advancing science and medicine in this area of unmet medical need, and it will continue to remain a focus for the organization. We are committed to making a difference in people's lives, and look forward to making EGRIFTATM available for patients as soon as possible. "

In 2008, Theratechnologies entered into a collaboration and licensing agreement with EMD Serono, for the exclusive commercialization rights to EGRIFTATM (tesamorelin for injection) in the United States for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy. Under the terms of this agreement, the FDA marketing approval is associated with milestone payments totaling US$25 million (approximately CAN$25 million). EGRIFTATM is the proposed brand name to be used globally.

The efficacy and safety of EGRIFTATM (tesamorelin for injection) was evaluated in two Phase 3 multi-center, randomized, double-blind, placebo-controlled clinical trials, which demonstrated statistically significant decreases in VAT and WC versus placebo in HIV-infected patients who suffer from excess abdominal fat associated with lipodystrophy.

The FDA has requested the following three post-marketing requirements: a long-term observational safety study for tesamorelin acetate (EGRIFTATM), a single vial formulation - the development of a new presentation of the same formulation, and a clinical trial to assess whether EGRIFTATM (tesamorelin for injection) has an impact on diabetic retinopathy in diabetic HIV-infected patients with lipodystrophy and excess abdominal fat.

"Having a FDA-approved treatment available for this condition is an important goal for the HIV population," said Steven Grinspoon, M.D., Professor of Medicine at Harvard Medical School, Director of the Massachusetts General Hospital Program in Nutritional Metabolism, and lead investigator for EGRIFTATM(tesamorelin for injection) trials in the U.S. "Although lifestyle modification could be a valuable first step for HIV patients with abdominal fat accumulation, results to date from lifestyle and exercise studies have been inconsistent with respect to the reduction in abdominal lipohypertrophy. Until today, physicians did not have access to approved drug options to treat this complication," added Dr. Grinspoon. "Having been involved in the clinical development of EGRIFTATM over the past 7 years, I am pleased that we have published data demonstrating that EGRIFTATM reduces VAT, with no adverse effects on subcutaneous adipose tissue. It is also important to monitor IGF-1 levels and impaired glucose tolerance in patients receiving EGRIFTATM. I am encouraged that, for the first time, patients in the United States with this serious condition will have a FDA-approved treatment option available to them," concluded Dr. Grinspoon.

Not too good news today

MK

Theratechnologies to Present at BioFinance 2010 Conference

MONTREAL, CANADA -- (MARKETWIRE) -- 04/05/10 --

Theratechnologies (TSX: TH) announced today that Yves Rosconi, President and
Chief Executive Officer, will present an overview of the Company at the
BioFinance 2010 Conference, being held this week in Toronto. Mr. Rosconi will
be speaking at 11:00 a.m., on Wednesday, April 7, in the Trinity II Room of the
Toronto Marriott Eaton Centre.

BioFinance is the Canadian life science industry's leading investor
conference that brings together key industry players to consider investment
opportunities and issues affecting companies in biotechnology.

About Theratechnologies

Theratechnologies (TSX: TH) is a Canadian biopharmaceutical company that
discovers and develops innovative therapeutic products, with an emphasis on
peptides, for commercialization. The Company targets unmet medical needs in
financially attractive specialty markets where it can retain all or part of the
commercial rights to its products. Its most advanced compound, tesamorelin, is
an analogue of the human growth hormone releasing factor. In 2009,
Theratechnologies submitted a New Drug Application to the U.S. Food and Drug
Administration, seeking approval of tesamorelin for the treatment of excess
abdominal fat in HIV-infected patients with lipodystrophy. The Company's growth
strategy is centered on the commercialization of tesamorelin in the United
States and in other markets for HIV-associated lipodystrophy, as well as the
development of clinical programs for tesamorelin in other medical conditions.

Contacts: Theratechnologies Inc. Andrea Gilpin Vice President, IR &
Communications 514-336-7800, ext. 205 communications@theratech.co

Click here to go to Dow Jones NewsPlus, a web front page of today's most
important business and market news, analysis and commentary:
http://www.djnewsplus.com/nae/al?rnd=zKXWTTW28PrVwqlfsS6Erg%3D%3D. You can use
this link on the day this article is published and the following day.


(END) Dow Jones Newswires

04-05-10 1037ET

no wonder....thanks for the info....eom

Theratechnologies Reports That the FDA Will Reschedule for Administrative Reasons the Advisory Committee Meeting to Review Tesamorelin's NDA

MONTREAL, QUEBEC, CANADA--(Marketwire - Jan. 25, 2010) - Theratechnologies (TSX:TH - News) today announced that the U.S. Food and Drug Administration ("FDA") will reschedule its meeting of the Endocrinologic and Metabolic Drugs Advisory Committee to review Theratechnologies' New Drug Application ("NDA") for tesamorelin. Originally scheduled for Wednesday, February 24, 2010, the meeting will be rescheduled due to an administrative delay at the FDA. The FDA informed Theratechnologies that this delay is entirely procedural and is not related to the tesamorelin NDA. A new meeting date will be announced shortly in the Federal Register.

Theratechnologies submitted an NDA to the FDA on May 29, 2009, for tesamorelin, an analogue of the growth hormone releasing factor, proposed for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy. The FDA filed the NDA on August 12, 2009, which initiated a substantive review of the application. The Prescription Drug User Fee Act ("PDUFA") date, which is the target date for the FDA to complete its review of tesamorelin's NDA, is March 29, 2010.

About HIV-Associated Lipodystrophy

Several factors including a patient's antiretroviral drug regimen and the HIV virus itself are thought to contribute to HIV-associated lipodystrophy, which is characterized by body composition changes, dyslipidemia and glucose intolerance. The changes in body composition include excess abdominal fat accumulation. There is currently no approved treatment available for the excess abdominal fat related to HIV-associated lipodystrophy, a condition that can stigmatize patients.

About Theratechnologies

Theratechnologies (TSX:TH - News) is a Canadian biopharmaceutical company with core expertise in peptide-based therapeutics. Its most advanced compound, tesamorelin, is an analogue of the human growth hormone releasing factor.

In late 2008, Theratechnologies completed its Phase 3 clinical program which was designed to evaluate tesamorelin in treating excess abdominal fat in HIV-infected patients with lipodystrophy. Theratechnologies signed a collaboration and licensing agreement with EMD Serono, Inc., for the commercialization of tesamorelin in the United States.

With a New Drug Application filed with the U.S. authorities in May 2009, Theratechnologies' growth strategy is firmly focused on the development of tesamorelin in the United States and in other potential HIV-associated lipodystrophy markets, as well as through additional clinical programs for other medical conditions.

No problem... Their drug is for a $600M market. ~60.4M shares outstanding, could hit $10 w/ an advisory committee vote in favor of approval, IMO.

GL.

awesome chart, found support above 50 sma...thanks for board creation.

PDUFA Date for tesamorelin is March 29, 2010.

Corporate Presentation PDF

http://theratech.com/docs/en/corpo/2010-01-04_TH_PresentationCorpo.pdf